AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027

AIM ImmunoTech Inc.

Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).
Entered Amendment #2 with Streeterville Capital, extending promissory note maturity to June 30, 2027; outstanding balance ~$1.68M.
Extension fee of $10,000 added to note balance; additional equity-generating funds raised since March 31.
CEO states amendment enhances capital allocation flexibility for pancreatic cancer program and other initiatives.

item 1.01item 2.02item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.